Patents by Inventor Bertrand Victor Gilbert Georges

Bertrand Victor Gilbert Georges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10300132
    Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 28, 2019
    Assignee: Altimmune UK Limited
    Inventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
  • Patent number: 9446143
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: September 20, 2016
    Assignee: ALTIMMUNE UK LIMITED
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Victor Gilbert Georges, Philip J. Sizer
  • Publication number: 20160106830
    Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 21, 2016
    Inventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
  • Publication number: 20160051661
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Application
    Filed: July 23, 2015
    Publication date: February 25, 2016
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
  • Patent number: 9119811
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 1, 2015
    Assignee: Vaxin UK Limited
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
  • Publication number: 20140234356
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 21, 2014
    Applicant: IMMUNE TARGETING SYSTEMS LTD.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Victor Gilbert Georges, Philip J. Sizer
  • Publication number: 20130330382
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Application
    Filed: December 30, 2011
    Publication date: December 12, 2013
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet